FDA Warning Letter to Ready Med Over Compounded GLP-1 Labels and "FDA Licensed Compounding Facility" Claim
On June 8, 2026, FDA issued a warning letter to Ready Med after a May 2026 review of readymednow.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "Ready Med" as if it were the compounder "when in fact it is not," and cites claims including "The same active ingredient in Mounjaro® and Zepbound™" and sourcing from an "FDA licensed compounding facility" — wording FDA calls "false and misleading." FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
Source: FDA original ↗